Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Docetaxel in Advanced Breast Cancer
NCT00055861Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2002
- Primary completion
- Aug 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by National Cancer Institute. Primary endpoints: Response rate at 4 years and Side effects at 4 years. Started Jul 2002; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00055861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055861.